Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Radiation Fibrosis Syndrome 2Pancreatic Neoplasms 2Pancreatic Adenocarcinoma 2Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Pancreatic Ductal Adenocarcinoma 1Osteosarcoma 1Neuroma, Acoustic 1Inflammation 1Fibrosis 1Fallopian Tube Neoplasms 1Carcinoma, Ovarian Epithelial 1Carcinoma, Hepatocellular 1Camurati-Engelmann Syndrome 1

Interventions

Paclitaxel 42Carboplatin 37Bevacizumab 29liposomal doxorubicin 20Taxes 18Specimen Handling 18pembrolizumab 16olaparib 16Magnetic Resonance Spectroscopy 16Gemcitabine 16Topotecan 13Immunoglobulin G 12Disulfides 12Biopsy 11niraparib 8mirvetuximab soravtansine 8Nivolumab 7Doxorubicin 7Cyclophosphamide 6Cisplatin 6Drug Therapy 5130-nm albumin-bound paclitaxel 5cemiplimab 4cediranib 4Letrozole 4Injections 4Docetaxel 41-dodecylpyridoxal 4sarilumab 3rucaparib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Fallopian Tube Neoplasms × Losartan × 1 year × Clear all
NCT07265739 2026-05-06

Losartan and Paclitaxel in Platinum Resistant Ovarian Cancer

Massachusetts General Hospital

Phase 2 Not yet recruiting
27 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡